FiercePharma12d
Eisai execs flag Leqembi 'expansion phase' on the horizon as Alzheimer's med grows slowly
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Two Alzheimer’s drugs help patients live independently at home for longer periods
Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.
Is The Alzheimer’s Drug Leqembi Covered By Medicare?
Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...
BioSpace11d
With Leqembi Sales Trending Up, Biogen Gets Down to Brass Tacks: It Works
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
Pharmabiz5d
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...
Yahoo Finance6d
Leqembi® sales reaches €200 million - first sales milestone achieved
The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment. Leqembi is the ...
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Leqembi® sales reaches €200 million - first sales milestone achieved
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...